Figitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1 receptor |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number |
943453-46-1  |
| ATC code | None |
| ChemSpider | none |
| UNII |
VE267FC2UB  |
| KEGG |
D09345 |
| Chemical data | |
| Formula | C6462H9948N1736O2020S54 |
| Molar mass | 146.0 kg/mol |
| (what is this?) (verify) | |
Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC).[3]
This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]
Anti-cancer mechanism
See Insulin-like growth factor 1 receptor role in cancer.
Clinical trials
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[5] but others continued.[6][7]
It was to be have been included in the I-SPY2 breast cancer trial.[8]
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
- ↑ Haluska, P; Worden, F; Olmos, D; Yin, D; Schteingart, D; Batzel, GN; Paccagnella, ML; De Bono, JS; et al. (2009). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer chemotherapy and pharmacology 65 (4): 765–773. doi:10.1007/s00280-009-1083-9. PMC 2875253. PMID 19649631.
- ↑ Gualberto, A; Karp, DD (2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical lung cancer 10 (4): 273–80. doi:10.3816/CLC.2009.n.038. PMID 19632947.
- ↑ "Cancer sufferer fears future without 'life-saver' drug". BBC News. July 2014.
- ↑ Krauskopf, Lewis (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters.
- ↑ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
- ↑ "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010.
This article is issued from Wikipedia - version of the Sunday, February 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.